Histological evaluation of PAXgene tissue fixation in Barrett’s esophagus and esophageal adenocarcinoma diagnostics

[1]  Po-Hsuan Cameron Chen,et al.  Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge , 2022, Nature Medicine.

[2]  T. Graham,et al.  Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy , 2021, Nature Reviews Gastroenterology & Hepatology.

[3]  A. Bass,et al.  Abnormal TP53 Predicts Risk of Progression in Patients With Barrett’s Esophagus Regardless of a Diagnosis of Dysplasia , 2020, medRxiv.

[4]  S. Killcoyne,et al.  Genomic copy number predicts esophageal cancer years before transformation , 2020, Nature Medicine.

[5]  Timo Kohlberger,et al.  An augmented reality microscope with real-time artificial intelligence integration for cancer diagnosis , 2019, Nature Medicine.

[6]  K. Strauch,et al.  BarrettNET-a prospective registry for risk estimation of patients with Barrett's esophagus to progress to adenocarcinoma. , 2019, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[7]  Thomas J. Fuchs,et al.  Clinical-grade computational pathology using weakly supervised deep learning on whole slide images , 2019, Nature Medicine.

[8]  Jakob Nikolas Kather,et al.  Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer , 2019, Nature Medicine.

[9]  H. El‐Serag,et al.  Prior Diagnosis of Barrett’s Esophagus Is Infrequent, but Associated with Improved Esophageal Adenocarcinoma Survival , 2018, Digestive Diseases and Sciences.

[10]  Marcela A. Salomao,et al.  Substantial Interobserver Agreement in the Diagnosis of Dysplasia in Barrett Esophagus Upon Review of a Patient’s Entire Set of Biopsies , 2017, The American journal of surgical pathology.

[11]  J. Goldblum,et al.  Discordance Among Pathologists in the United States and Europe in Diagnosis of Low-Grade Dysplasia for Patients With Barrett's Esophagus. , 2017, Gastroenterology.

[12]  M. Ilyas,et al.  Dysplasia in Barrett's oesophagus: p53 immunostaining is more reproducible than haematoxylin and eosin diagnosis and improves overall reliability, while grading is poorly reproducible , 2016, Histopathology.

[13]  P. Martinez,et al.  Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus , 2016, Nature Communications.

[14]  Fay Betsou,et al.  A Critical Evaluation of the PAXgene Tissue Fixation System:  Morphology, Immunohistochemistry, Molecular Biology, and Proteomics. , 2016, American journal of clinical pathology.

[15]  N. Shaheen,et al.  Corrigendum: ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus , 2016, The American Journal of Gastroenterology.

[16]  Kenneth K Wang,et al.  Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis. , 2016, Gastroenterology.

[17]  Nicholas J Shaheen,et al.  ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus , 2016, The American Journal of Gastroenterology.

[18]  I. Tomlinson,et al.  Genetic Biomarkers of Barrett’s Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis , 2015, Digestive Diseases and Sciences.

[19]  S. El Hallani,et al.  Evaluation of Quantitative Digital Pathology in the Assessment of Barrett Esophagus-Associated Dysplasia. , 2015, American journal of clinical pathology.

[20]  Carissa A. Sanchez,et al.  Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus , 2015, Cancer Prevention Research.

[21]  Helen M. Moore,et al.  Accuracy of Molecular Data Generated with FFPE Biospecimens: Lessons from the Literature. , 2015, Cancer research.

[22]  Takeshi Yamaguchi,et al.  Comprehensive DNA Methylation and Extensive Mutation Analyses of HER2-Positive Breast Cancer , 2015, Oncology.

[23]  R. Fitzgerald,et al.  Targeting care in Barrett's oesophagus. , 2014, Clinical medicine.

[24]  Helen M. Moore,et al.  A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen? , 2014, Archives of pathology & laboratory medicine.

[25]  G. Kayser,et al.  Evaluation of colon cancer histomorphology: a comparison between formalin and PAXgene tissue fixation by an international ring trial , 2014, Virchows Archiv.

[26]  F. Vleggaar,et al.  Surveillance of Barrett's Esophagus and Mortality from Esophageal Adenocarcinoma: A Population-Based Cohort Study , 2014, The American Journal of Gastroenterology.

[27]  Rebecca C Fitzgerald,et al.  British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus , 2013, Gut.

[28]  Stefan Heldmann,et al.  MRI-compatible pipeline for three-dimensional MALDI imaging mass spectrometry using PAXgene fixation. , 2013, Journal of proteomics.

[29]  Jorma Isola,et al.  Preservation of nucleic acids and tissue morphology in paraffin-embedded clinical samples: comparison of five molecular fixatives , 2013, Journal of Clinical Pathology.

[30]  K. Zatloukal,et al.  The PAXgene® Tissue System Preserves Phosphoproteins in Human Tissue Specimens and Enables Comprehensive Protein Biomarker Research , 2013, PloS one.

[31]  C. Compton,et al.  Non-formalin fixative versus formalin-fixed tissue: a comparison of histology and RNA quality. , 2013, Experimental and molecular pathology.

[32]  P. Riegman,et al.  A new technology for stabilization of biomolecules in tissues for combined histological and molecular analyses. , 2012, The Journal of molecular diagnostics : JMD.

[33]  L. Lovat,et al.  Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. , 2011, Gastroenterology.

[34]  Kurt Zatloukal,et al.  Histological Assessment of PAXgene Tissue Fixation and Stabilization Reagents , 2011, PloS one.

[35]  H. Sørensen,et al.  Incidence of adenocarcinoma among patients with Barrett's esophagus. , 2011, The New England journal of medicine.

[36]  Helen M. Moore,et al.  Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. , 2011, Archives of pathology & laboratory medicine.

[37]  Prateek Sharma,et al.  American Gastroenterological Association technical review on the management of Barrett's esophagus. , 2011, Gastroenterology.

[38]  Kurt Zatloukal,et al.  Proteomic analysis of PAXgene-fixed tissues. , 2010, Journal of proteome research.

[39]  E. Espinosa,et al.  Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues. , 2010, BioTechniques.

[40]  Carissa A. Sanchez,et al.  Genetic clonal diversity predicts progression to esophageal adenocarcinoma , 2006, Nature Genetics.

[41]  J K Greenson,et al.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. , 2001, Human pathology.

[42]  M F Dixon,et al.  The Vienna classification of gastrointestinal epithelial neoplasia , 2000, Gut.

[43]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[44]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .